Nature Reviews Drug Discovery

FDA approves 100th small-molecule kinase inhibitor

Asher Mullard Dec 01, 2025 pp. 891-895 10.1038/d41573-025-00188-7

“It’s about time”: Tregs win the Nobel prize

Asher Mullard Dec 01, 2025 pp. 900-901 10.1038/d41573-025-00186-9

CAR-T cells drive into progressive multiple sclerosis

M. Teresa Villanueva Dec 01, 2025 pp. 905-905 10.1038/d41573-025-00184-x

Lilly’s tirzepatide and Novo Nordisk’s semaglutide vie for top drug spot

Asher Mullard Dec 01, 2025 pp. 897-897 10.1038/d41573-025-00183-y

CRISPR activation tackles neurodevelopmental disorders

Katie Kingwell Dec 01, 2025 pp. 905-905 10.1038/d41573-025-00179-8

Novartis pays US$12 billion for Avidity’s lead antibody–oligonucleotide drugs

Asher Mullard Dec 01, 2025 pp. 896-896 10.1038/d41573-025-00182-z

Cancer cell therapies: global clinical trial trends and emerging directions

Fahad Benthani, Samik Upadhaya, Alicia Zhou Dec 01, 2025 pp. 898-899 10.1038/d41573-025-00180-1

FDA approves PDE4 inhibitor for IPF

Asher Mullard Dec 01, 2025 pp. 896-896 10.1038/d41573-025-00181-0

Targeting the ECM in melanoma

Sarah Crunkhorn Dec 01, 2025 pp. 906-906 10.1038/d41573-025-00176-x

Designing insulin receptor agonists

Sarah Crunkhorn Dec 01, 2025 pp. 906-906 10.1038/d41573-025-00175-y

Blocking tick-borne encephalitis

Sarah Crunkhorn Dec 01, 2025 pp. 906-906 10.1038/d41573-025-00174-z

PROTAC for p300/CBP in prostate cancer

Sarah Crunkhorn Dec 01, 2025 pp. 906-906 10.1038/d41573-025-00177-w

Lectin-based bispecific targets tumour-associated glycans

Alex Eccleston Dec 01, 2025 pp. 904-904 10.1038/d41573-025-00173-0

Designing error-free prime editors

Sarah Crunkhorn Dec 01, 2025 pp. 904-904 10.1038/d41573-025-00172-1

The evolution of the obesity drug market

Carles Recasens-Alvarez, Gideon Heap, Graeme Green Dec 01, 2025 pp. 902-903 10.1038/d41573-025-00155-2

How multispecific molecules are transforming pharmacotherapy

Raymond J. Deshaies Dec 01, 2025 pp. 945-957 10.1038/s41573-025-01262-w

Advances in the treatment of systemic lupus erythematosus

Marc Scherlinger, Antonios G. A. Kolios, Vasileios C. Kyttaris et al. Dec 01, 2025 pp. 926-944 10.1038/s41573-025-01242-0

CRISPR-based therapeutic genome editing for inherited blood disorders  

Sébastien Levesque, Daniel E. Bauer Dec 01, 2025 pp. 907-925 10.1038/s41573-025-01236-y

Delivering regulatory impact from consortium-based projects

Martha A. Brumfield, Graham C. Higson, Cécile Ollivier et al. Dec 01, 2025 pp. 889-890 10.1038/d41573-025-00098-8